Overexpression of PLAU has been identified as a promising therapeutic target for inhibition in (co)treatment of triple negative breast cancer in multiple studies [1,8,9,10], including ours [20,28]. The gene discussed is PLAU; the disease is triple-negative breast carcinoma.